Biodesix Presentation at Molecular Med Tri-Conference: “Blood-Based Cancer Immunotherapy Diagnostics”

Chief Technology Officer for Biodesix, Inc., Dr. Heinrich Roder, will present the company’s approach and recent results for a blood test stratifying patients for immunotherapy benefit on Thursday, March 10, at Molecular Med Tri-Conference.

By modifying ideas from the field of deep learning, Biodesix^® can design clinically useful tests from multivariate data that have a high likelihood of validating in independent clinical sets, overcoming the “false test discovery” problem. Dr. Roder’s presentation will review how the combination of high dimensional protein data and deep learning techniques can be used to design blood-based, clinically-actionable, multivariate tests that are making key inroads in precision medicine.

While many patients obtain some level of benefit from immunotherapies, there is a subset of patients who do particularly well on anti-PD1 agents and achieve long-term survival. A diagnostic blood test to stratify patients based on potential benefit addresses a critical unmet need. Dr. Roder will present recent results of a serum-based test for patients with metastatic melanoma to identify those likely to achieve long-term benefit from anti-PD1 immunotherapy.

Details of the presentation are as follows:

Symposia: Biomarkers for Cancer Immunotherapy: Predictive and Prognostic Biomarkers for Immunotherapy

Date: 03/10/2016, 10:25 AM – 10:40 AM

Location: Hilton SF Union Square Hotel, Imperial A

VeriStrat and Biodesix are registered trademarks of Biodesix, Inc.  All other trademarks referenced herein are the property of their respective owners.

About Biodesix
Biodesix® is a molecular diagnostics company advancing the development of innovative blood-based tests in oncology to enable precision medicine. Biodesix discovers, develops and commercializes multivariate protein and genomic diagnostic blood tests, including GeneStrat™ and VeriStrat®, that deliver results within 72 hours. The company is changing the standard of care by providing physicians with diagnostic tests for better therapeutic guidance, more accurate prognosis and enhanced disease monitoring to improve patient outcomes. At the forefront of precision medicine, Biodesix is developing new blood tests to identify patients who may benefit from immunotherapies. In addition to developing novel diagnostics independently, the company partners with biotechnology and pharmaceutical companies to develop companion diagnostics for use with therapeutic agents.